| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus.
|
Antimicrob Agents Chemother
|
2005
|
4.22
|
|
2
|
Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains.
|
Antimicrob Agents Chemother
|
2005
|
2.72
|
|
3
|
In vitro activity of TD-6424 against Staphylococcus aureus.
|
Antimicrob Agents Chemother
|
2003
|
2.60
|
|
4
|
Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study.
|
Crit Care Med
|
2008
|
2.37
|
|
5
|
Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria.
|
Antimicrob Agents Chemother
|
2004
|
2.17
|
|
6
|
Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria.
|
J Antimicrob Chemother
|
2004
|
2.01
|
|
7
|
In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
|
J Antimicrob Chemother
|
2007
|
1.93
|
|
8
|
Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
|
Clin Ther
|
2008
|
1.78
|
|
9
|
Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study.
|
Curr Med Res Opin
|
2008
|
1.18
|
|
10
|
A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia.
|
Crit Care
|
2012
|
1.18
|
|
11
|
Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus.
|
Antimicrob Agents Chemother
|
2005
|
1.17
|
|
12
|
Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests.
|
J Antimicrob Chemother
|
2005
|
1.12
|
|
13
|
Exploring the positional attachment of glycopeptide/beta-lactam heterodimers.
|
J Antibiot (Tokyo)
|
2008
|
1.01
|
|
14
|
Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients.
|
Antimicrob Agents Chemother
|
2010
|
0.98
|
|
15
|
In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis.
|
Antimicrob Agents Chemother
|
2005
|
0.92
|
|
16
|
A multivalent approach to drug discovery for novel antibiotics.
|
J Antibiot (Tokyo)
|
2008
|
0.84
|
|
17
|
Activity of doripenem versus comparators in subjects with baseline bacteraemia in six pooled phase 3 clinical trials.
|
Int J Antimicrob Agents
|
2013
|
0.81
|
|
18
|
In vitro Etest synergy of doripenem with amikacin, colistin, and levofloxacin against Pseudomonas aeruginosa with defined carbapenem resistance mechanisms as determined by the Etest method.
|
Diagn Microbiol Infect Dis
|
2012
|
0.78
|
|
19
|
Meta-analysis of doripenem vs comparators in patients with pseudomonas infections enrolled in four phase III efficacy and safety clinical trials.
|
Curr Med Res Opin
|
2009
|
0.77
|